No, do not give olanzapine as first-line treatment for suspected catatonia
Benzodiazepines (specifically lorazepam) are the established first-line treatment for catatonia, not olanzapine. The evidence consistently supports benzodiazepines as both diagnostic and therapeutic agents, with a 77% overall response rate and 55% remission rate 1. Olanzapine and other antipsychotics should only be considered after benzodiazepine trials have been attempted or in specific clinical contexts.
Treatment Algorithm for Suspected Catatonia
First-Line: Benzodiazepines
- Start with lorazepam at 1-2 mg IV/IM or PO as a diagnostic challenge
- If positive response (improvement within 30 minutes to 2 hours), continue lorazepam at 2-8 mg/day in divided doses (median effective dose 8 mg/day, range 2-60 mg/day) 1
- Treatment duration typically does not exceed 1 week for acute response 1
- Response rate to benzodiazepines is approximately 77%, with 55% achieving remission 1
When to Consider Antipsychotics
Olanzapine may be considered in these specific scenarios:
Catatonia with prominent psychotic symptoms in schizophrenia - where the underlying psychotic disorder requires treatment, but outcomes are mixed 2, 3
Partial response to benzodiazepines - combination therapy with lorazepam plus olanzapine may be more effective than either alone 4
After adequate benzodiazepine trial fails - though ECT should be strongly considered before or concurrent with antipsychotic use
Critical Warnings About Olanzapine in Catatonia
The evidence for olanzapine in catatonia is equivocal at best:
- A 2025 systematic review found olanzapine associated with "mitigated reported outcomes" - meaning mixed beneficial and non-beneficial results 2
- Only 60% of antipsychotic trials showed benefit, 29.1% were neutral, and 10.9% were harmful 2
- Olanzapine specifically showed equivocal outcomes across multiple case reports 2
Important caveat: Catatonia in schizophrenia is notably more resistant to benzodiazepine treatment than catatonia from other causes 4. In first-episode psychotic patients with catatonia, antipsychotics (including olanzapine) showed good response when catatonia remission was tied to psychotic symptom resolution 3.
FDA-Approved Indications
Olanzapine is NOT FDA-approved for catatonia treatment 5. The FDA label lists approved indications as:
- Schizophrenia
- Bipolar I disorder (manic or mixed episodes)
- Agitation associated with schizophrenia and bipolar mania
- Depressive episodes in bipolar disorder (with fluoxetine)
- Treatment-resistant depression (with fluoxetine)
Notably, the FDA label warns about Neuroleptic Malignant Syndrome (NMS) as a serious adverse effect requiring immediate discontinuation 5. NMS shares clinical features with malignant catatonia, making antipsychotic use potentially risky in undifferentiated catatonia.
Recommended Approach
Confirm catatonia diagnosis using Bush-Francis Catatonia Rating Scale (look for ≥3 signs: mutism, posturing, waxy flexibility, negativism, rigidity, echophenomena)
Rule out medical causes and NMS (fever, autonomic instability, elevated CK)
Lorazepam challenge: 1-2 mg IV/IM/PO, assess response in 30 minutes to 2 hours
If positive response: Continue lorazepam 6-24 mg/day in divided doses
If inadequate response after 48-72 hours at adequate doses: Consider ECT (highly effective, especially for malignant catatonia) 6
If psychotic symptoms are prominent AND catatonia persists despite benzodiazepines: Consider adding olanzapine 5-10 mg/day while continuing lorazepam 4
Monitor closely for worsening catatonia or emergence of NMS features when using antipsychotics
Special Populations
In adolescents with neurodevelopmental disorders and catatonia with psychotic symptoms, antipsychotic use showed variable outcomes with 60% having CGI-I ≤3 after first antipsychotic trial, but 10% worsened 7. ECT was frequently needed (60% of cases) 7.
Alternative to consider: Zolpidem (another GABA-A modulator) showed 84.8% response rate in catatonia at mean dose 14.7 mg, with rapid response (mean 30 minutes), though evidence is limited to case reports 8.